Packer M
Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York.
Cardiovasc Drugs Ther. 1989 Jan;2(6):743-6. doi: 10.1007/BF00133202.
Controlled trials using modern methods of assessment in well-defined groups of patients have now convincingly demonstrated that digitalis is an effective and well-tolerated drug in patients with chronic heart failure who have left ventricular systolic dysfunction. These encouraging findings concerning digitalis, however, should not be construed to suggest that the drug should be used alone in the treatment of heart failure. Digitalis cannot adequately control the fluid retention seen in most patients with chronic heart failure; diuretics should be added to maintain sodium balance. Digitalis has not been shown to prolong life in chronic heart failure; converting-enzyme inhibitors should be added to reduce morbidity and mortality. All three drugs should be used together in the management of patients with this disorder.
运用现代评估方法在明确界定的患者群体中进行的对照试验现已令人信服地表明,对于患有左心室收缩功能障碍的慢性心力衰竭患者,洋地黄是一种有效且耐受性良好的药物。然而,这些关于洋地黄的令人鼓舞的发现不应被理解为暗示该药物应单独用于治疗心力衰竭。洋地黄无法充分控制大多数慢性心力衰竭患者出现的液体潴留;应添加利尿剂以维持钠平衡。尚未证明洋地黄能延长慢性心力衰竭患者的生命;应添加转换酶抑制剂以降低发病率和死亡率。在管理患有这种疾病的患者时,这三种药物应一起使用。